A method of powderizing a dry cake pharmaceutical drug product for injection within a vial may include securing a vial containing a dry cake pharmaceutical drug product for injection to a shaker device and powderizing the dry cake pharmaceutical drug product within the vial by shaking the vial with the shaker device operated at between about 100 to about 5000 cycles per minute for between about 10 minutes and about 1 hour.

A glass vial includes a base including a boron-containing multicomponent glass and a vial opening and holds a liquid active pharmaceutical ingredient formulation. The glass vial has a total volume of <4.5 mL. A filling level of the glass vial with the active pharmaceutical ingredient formulation is not more than 0.25 and a concentration of boron ions, measured at a measurement site below a plane of a middle of the glass vial using a concentration depth profile at a depth in a range from 10 to 30 nm, has a value, averaged over the measurements of the concentration depth profile, that has an excess increase of not more than 30% compared to a concentration of boron ions measured using a concentration depth profile at a depth in a range from 10 to 30 nm with a measurement site in the plane of the middle of the glass vial.

A vial adapter assembly that includes a housing, a first receptacle formed within the housing and configured to receive a first vial within the housing, and a second receptacle formed within the housing and configured to receive a second vial within the housing. An opening of the first receptacle and an opening of the second receptacle is in fluid communication with the upper surface of the housing. The vial adapter assembly includes a cap that is coupled and movable relative to the housing from a closed configuration to an open configuration. In the closed configuration, the cap is configured to cover the opening of the first receptacle and the opening of the second receptacle on the upper surface. In the open configuration, the cap is configured to uncover the opening of the first receptacle and the opening of the second receptacle, and expose the upper surface.

A biobased polymer composition for pharmaceutical articles includes a low density polyethylene, in which at least a portion of ethylene is obtained from a renewable source of carbon. The biobased polymer composition exhibits an Emission Factor ranging from −3.5 to 0 kg CO2.sub.e/kg of the biobased polymer composition, and is biocompatible for use in pharmaceutical packaging. A pharmaceutical article includes the biobased polymer composition and has a volume ranging from 0.04 ml to 10000 ml. A method for forming a pharmaceutical article includes extruding the biobased polymer composition at a temperature ranging from 100 to 250° C. and at a screw speed ranging from 20 to 100 rpm. A method for producing a biobased polymer composition includes polymerizing ethylene at least partially obtained from a renewable source of carbon to form a low density polyethylene.

Mechanisms for dispensing items such as medications and medical supplies. Different mechanisms may be tailored to dispensing different kinds of items, for example medications in single dose packages, vials, syringes, or other similarly-shaped items. The dispensers may be placed in a dispensing unit that includes a lockable restock drawer and a dispense drawer into which items are dispensed by the dispensing mechanisms. The various kinds of dispensing mechanisms may be installed in the restock drawer in any workable proportion and arrangement. The dispensing mechanisms include multiple sensing technologies for tracking and inventory of items and for accurate sensing of items as they are dispensed.

A medicine dispensing device, configured to contain a liquid medicine to be dispensed by the medicine dispensing device and having a plurality of dosing indicia spaced apart from each other around and in relation to a circumference of a surface of the medicine dispensing device, each dosing indicia being of a different height relative to a reference level and corresponding to different dose of the liquid medicine.

A quartz glass container is shown and described herein. The quartz glass container exhibits a low concentration of surface defects on an inner surface of the container. In aspects hereof, the container may have a surface defect density of 50 or fewer surface defects per square centimeter within a 1 cm band centered 1 cm from the base of the container.

The embodiments of the present disclosure provide a pierceable stopper, comprising a plug portion, and a disk portion disposed on top of the plug portion and comprising a flange extending radially beyond an outer diameter of the plug portion. The embodiments also provide a lyophilization stopper, comprising a body comprising an integral hinge means, and a flange extending radially beyond an outer diameter of the body. Additionally, the embodiments provide a probe assembly, comprising a first needle comprising a hollow cavity and a pointed tip, and a second needle disposed inside the hollow cavity and comprising a rounded tip. The embodiments further provide a cartridge assembly, comprising a first housing comprising a first set of cavities configured to accommodate one or more containers, and a second housing comprising a second set of cavities corresponding to the first set of cavities when the second housing is coupled to the first housing.

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

A vial blinding assembly includes a vial having a bottle with a constricted neck and an annular shoulder that inwardly extends; a stopper disposed on an opening of the bottle and having a septum with a top surface; and a retainer securing the stopper to the bottle. A tubular blinding shell encircles a compartment that extends between a first end with an inlet opening and an opposing second end with an access opening. A floor plug is secured to the first end of the blinding shell. The vial is disposed within compartment of the blinding shell with the vial being supported by the floor plug and the neck passing through the access opening so that the top surface of the septum is disposed outside of the compartment of the blinding shell, the shoulder of the vial having an outside diameter larger than a diameter of the access opening.